开放标签的3期POSEIDON研究在转移性非小细胞肺癌(mNSCLC)一线治疗中评估了tremelimumab + durvalumab和化疗(T + D+CT)以及durvalumab +化疗(D+CT)与单独化疗(CT)的疗效。 METHODS 方法 Patients (n=1,013) with EGFR/ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalu...
However, real world outcomes on this regimen have not been described.Methods:In the context of a prospectively maintained database including 953 patients (pts) with unresectable HCC treated with immunotherapy, we analysed a subgroup of pts treated with STRIDE or DUR across 5 centres in USA, Asia...
This translated to a 24% reduction in the risk of disease progression or death (HR, 0.76; 95% CI, 0.61-0.95; P =.0161). In ADRIATIC, investigators sought to assess the role of durvalumab with or without tremelimumab (Imjudo) as consolidation therapy following concurrent chemoradiation in ...
ADRIATIC, a phase III, randomized, double-blind, placebo-controlled, multicenter, global study (ClinicalTrials.gov identifier, NCT03703297), is designed to investigate the efficacy of durvalumab, with or without tremelimumab, as consolidation therapy for patients with LS-SCLC without disease progression...
We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer. Methods:This open-label, single-centre, phase 2 study was conducted at Seoul National University Hospital. Eligible patients were treatment...
The study authors noted that the individuals were randomly assigned to receive 1500 mg of durvalumab with or without 75 mg of tremelimumab, every 4 weeks for 4 doses/cycles each, then continued with tremelimumab every 4 weeks for 24 months. The study had dual primary endpoints ...
Patients with mPDAC (n = 180) were randomized to two treatment arms: gemcitabine, nab-paclitaxel, durvalumab and tremelimumab (hereafter referred to as ‘chemo+ICI’; n = 119) or gemcitabine and nab-paclitaxel (‘chemo’; n = 61; Supplementary Fig. 1). Treatment was initiated...
The phase 3 KESTREL trial demonstrated that combination treatment with durvalumab plus tremelimumab did not display an overall survival benefit in “all-comer” patients with metastatic head and neck squamous cell carcinoma versus the EXTREME regimen....
Patients with treatment-naive, metastatic NSCLC without sensitizing EGFR or ALK alterations were randomized (1:1) to receive treatment with durvalumab plus tremelimumab with or without platinum-doublet chemotherapy. The primary end point was overall survival (OS). Secondary end points were progression-...
Peters S, Chul Cho B, Luft A et al. LBA3 – Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study. Abstract presented at ESMO Immuno-Oncology Congress 2023, December 6-8, 2023. ...